Official Release Repository: ACIP

ACIP recommends 21-valent PCV (PCV21) as an option for adults aged 19 years and older who are currently recommended to receive PCV15 or PCV20

ACIP Recommendations – September 12, 2024

ACIP recommends that Vaxelis [DTaP-IPV-Hib-HepB]) be included with monovalent PRP-OMP (Pedvax Hib)in the preferential recommendation for AI/AN infants based on the Hib component

ACIP Recommendations – September 12, 2024

ACIP recommends use of the 2024-25 COVID-19 vaccines for persons six months and older

ACIP Recommendations – September 10, 2024

ACIP Recommendations: Prevention and Control of Seasonal Influenza with Vaccines, US, 2024–25 Influenza Season

ACIP Recommendations – August 29, 2024

ACIP recommendations for the use of respiratory syncytial virus (RSV) vaccines in adults 60 years and older

ACIP – August 6, 2024

CDC approves ACIP recommendations for RSV for adults, DTaP-IPV-Hib-HepB (Vaxelis®️), COVID-19, Influenza, and Pneumococcal Vaccines

ACIP meeting – June 28, 2024

ACIP recommends use of an additional updated 2023–2024 COVID-19 vaccine dose for adults aged 65 Years and older

ACIP Recommendations – April 25, 2024

ACIP recommendations for use of pentavalent meningococcal vaccine (Pfizer) for persons 10 years and older

ACIP Recommendations – April 18, 2024

CDC endorses ACIP recommendations for additional dose 2023-24 COVID-19 vaccine for adults ages 65 years and older and Chikungunya vaccine for travelers and lab workers

ACIP meeting – February 28, 2024

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024

ACIP – January 11, 2024

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024

ACIP – January 11, 2024

ACIP recommends Inactivated Polio Vaccine (IPV) for all adults 18 years and older known or suspected to be unvaccinated or incompletely vaccinated against polio

ACIP Recommendations – December 8, 2023

ACIP recommends use of Tick-Borne Encephalitis (TBE) vaccine for certain travelers and any laboratory workers who work with the virus

ACIP Recommendations – November 10, 2023

ACIP recommends use of updated COVID-19 vaccines for persons 6 months of age and older

ACIP Recommendations – October 10, 2023

ACIP recommends RSV vaccine (Abrysvo, Pfizer) for pregnant persons at 32–36 weeks' gestation using seasonal administration (September–January in most of the United States) to prevent RSV-associated lower respiratory infections in infants less than 6 months of age

ACIP Recommendations – October 6, 2023

ACIP recommendations on the use of PCV20 (Pfizer) for children

ACIP Recommendations – September 29, 2023

Recommendations for Prevention and Control of Influenza in Children, 2019–2020 - AAP Policy Statement

AAP Policy Statement – September 19, 2023

ACIP recommendations for the use of pneumococcal vaccines in adults 19 years of age and older

ACIP Recommendations – September 8, 2023

ACIP recommendations on use of nirsevimab (Beyfortus, Sanofi) for infants aged less than 8 months born during or entering their first RSV season and for infants and children aged 8–19 months who are at increased risk of severe RSV disease entering their second RSV season.

ACIP Recommendations – August 25, 2023

Prevention and Control of Seasonal Influenza with Vaccines, 2023-24

ACIP Recommendations – August 25, 2023

ACIP recommendations on use of Respiratory Syncytial Virus (RSV) vaccines (Pfizer Abrysvo and GSK Arexvy) in older adults

ACIP Recommendations – July 21, 2023

ACIP interim recommendations for use of bivalent mRNA vaccines for persons aged 6 months – 5 years, adults 65 and older, and for those with immunocompromising conditions

ACIP Recommendations – June 16, 2023

Updated Recommendation from ACIP for Use of Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — U.S. April 2021

ACIP Recommendations – April 27, 2023

ACIP recommends Priorix (GSK) as an additional option to prevent MMR according to existing vaccine recommendations and off-label uses, US, 2022

ACIP Recommendations – November 18, 2022

ACIP interim recommendations for the use of bivalent booster doses of COVID-19 vaccines, US October 2022

ACIP Recommendations – November 11, 2022

ACIP recommendation for the use of cholera (Vaxchora, Emergent Biosolutions) vaccine

ACIP Recommendations – September 30, 2022

ACIP recommends use of PCV15 as an option for pneumococcal vaccination for children under 19 years of age, using currently recommended PCV13 dosing and schedules

ACIP Recommendations – September 16, 2022

Prevention and Control of Seasonal Influenza with Vaccines, 2022-23

ACIP Recommendations – August 26, 2022

ACIP interim recommendation for use of Novavax COVID-19 vaccine in adults 18 years and older, US, July 2022

ACIP – August 5, 2022

ACIP interim recommendations for use of Moderna and Pfizer-BioNTech COVID-19 vaccines in children aged 6 Months–5 Years — US, June 2022

ACIP – June 28, 2022

ACIP recommendations for use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses, US, 2022

ACIP Recommendations – May 27, 2022

ACIP updates rabies vaccine recommendations - Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies, US, 2022

ACIP Recommendations – May 6, 2022

ACIP recommends universal hepatitis B vaccination in adults aged 19-59 Years, US, 2022

ACIP Recommendations – April 1, 2022

ACIP Recommendation for use of Moderna COVID-19 Vaccine in Adults aged 18 years and older, considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines — US, February 2022

ACIP Recommendations – March 18, 2022

Use of Ebola Vaccine: Expansion of ACIP Recommendations to include two additional populations, US, 2021.

ACIP Recommendations – February 25, 2022

ACIP updates recommendations for adults on use of 15-Valent Pneumococcal Conjugate Vaccine (Vaxneuvance, Merck) PCV15 and 20-Valent Pneumococcal Conjugate Vaccine (Prevnar 20, Pfizer), US, 2022.

ACIP Recommendations – January 28, 2022

ACIP Recommendations for Use of Recombinant Zoster Vaccine (RZV, Shingrix, GSK) in Immunocompromised Adults aged 19 years and older, US, 2022.

ACIP Recommendations – January 21, 2022

ACIP Updated Interim Recommendations for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine, US, December 2021.

ACIP Recommendations – January 21, 2022

ACIP Recommendations on Dengue Vaccine, US, 2021.

ACIP Recommendations – December 17, 2021

ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - US, 2021

ACIP Recommendations – November 5, 2021

ACIP Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines – US, 2021

ACIP Recommendations – October 29, 2021

Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021

ACIP Recommendations – September 21, 2021

Prevention and Control of Seasonal Influenza with Vaccines, 2021-22

ACIP Recommendations – August 27, 2021

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update ACIP, July 2021

ACIP Recommendations – August 13, 2021

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from ACIP - US, June 2021

ACIP Recommendations – July 6, 2021

ACIP Interim Recommendations for use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 years, US, May 2021

ACIP Recommendations – May 14, 2021

ACIP Interim Recommendation for Use of Janssen (Johnson and Johnson) COVID-19 Vaccine - U.S., February 2021

ACIP Recommendations – March 2, 2021

2021 U.S. Recommended Immunization Schedules for Children and Adolescents Age 18 Years or Younger

ACIP/AAP/AAFP/ACOG Recommendations – February 12, 2021

2021 U.S. Recommended Immunization Schedule for Adults Aged 19 Years or Older

ACIP/AAFP/ACP/ACOG/ACNM – February 12, 2021

Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, U.S., 2020

ACIP Recommendations – January 8, 2021

ACIP Updated Interim Recommendation for Allocation of COVID-19 Vaccine - U.S., December 2020

ACIP Recommendations – December 22, 2020

ACIP Interim Recommendation for Use of Moderna COVID-19 Vaccine - U.S, December 2020

ACIP Recommendations – December 20, 2020

ACIP Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - U.S., December 2020

ACIP Recommendations – December 13, 2020

ACIP Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - U.S., 2020

ACIP Recommendations – December 3, 2020

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices

ACIP Recommendations – September 25, 2020

Prevention and Control of Seasonal Influenza with Vaccines, 2020 - 2021

ACIP Recommendations – August 21, 2020

Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices

ACIP Recommendations – July 3, 2020

2020 U.S. Recommended Immunization Schedules for Children and Adolescents Age 18 Years or Younger

ACIP/AAP/AAFP/ACOG – February 7, 2020

2020 U.S. Recommended Immunization Schedule for Adults Aged 19 Years or Older

ACIP/AAFP/ACP/ACOG/ACNM – February 7, 2020

Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants

ACIP Recommendations – February 7, 2020

Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices

ACIP Recommendations – January 24, 2020

Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019

ACIP Recommendations – December 13, 2019

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years and older: Updated Recommendations of the Advisory Committee on Immunization Practices

ACIP Recommendations – November 22, 2019

Prevention and Control of Seasonal Influenza with Vaccines, 2019-2020

ACIP Recommendations – August 23, 2019

Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices

ACIP Recommendations – August 16, 2019

Vaccine Topics

General Topics

Patient Safety Honor Rolls

Our Affiliated Sites